More on BIIB
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $199.95 |
|
|||
| Open | $199.95 | ||||
| 52 Wk High | $333.65 | ||||
| 52 Wk Low | $223.02 | ||||
| Day High | $199.95 | ||||
| Day Low | $199.95 | ||||
| P/E | 25.60 | ||||
| EPS | $7.81 | ||||
| Volume | 2,844 | ||||
- Biogen (BIIB) PT Raised to $280 at Guggenheim
- Biogen (BIIB) PT Lowered to $215 at BofA Securities
- Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide
- FDA approves Leqembi Iqlik subcutaneous injection for Alzheimer's
- Biogen names Michael J. Parini as chief legal officer
- Biogen Appoints Michael J. Parini as Chief Legal Officer
- Biogen tumbles 8.7% as breakthrough Alzheimer’s data is clouded by dosing paradox
- Real-world Leqembi study shows 82% of Alzheimer's patients stable
- LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Tre
- Biogen Phase 2 data shows diranersen slows Alzheimer's decline
Entities mentioned with BIIB
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Options | View Related Stories »
- Show More...
